CDC Advisory Committee on Immunization Practices
Pfizer and Valneva’s application for Lyme disease vaccine candidate validated by EMA
There are currently no approved human vaccines for Lyme disease
MHRA approves Valneva’s chikungunya vaccine Ixchiq for use in adults
The chikungunya virus has now been identified in over 110 countries in Europe, Asia, Africa and the Americas
Valneva shares positive phase 3 results for chikungunya vaccine in adolescents
The company has submitted label extension applications for Ixchiq in this age group
Pfizer/Valneva share promising results for Lyme disease vaccine candidate
There are currently no approved human vaccines for the bacterial infection
Valneva and LimmaTech Biologics partner to advance Shigella vaccine candidate
There is currently no vaccine approved for Shigella, the second leading cause of fatal diarrhoeal disease globally
EC approves Valneva’s single-dose chikungunya vaccine for use in adults
The virus has been identified in over 110 countries in Europe, Asia, Africa and the Americas
CHMP recommends Valneva’s chikungunya vaccine for use in adults
If approved, Ixchiq will become the first vaccine available in the EU for the mosquito-borne viral disease
Valneva’s single-dose chikungunya vaccine shows promise in adolescents
The mosquito-borne viral disease often causes sudden, large outbreaks with high attack rates
Valneva’s chikungunya virus vaccine recommended by US CDC advisory committee
The mosquito-borne viral disease leads to symptomatic disease in 97% of people within a week or less following the mosquito bite
Valneva sells FDA priority review voucher for chikungunya vaccine for $103m
The company received a tropical disease PRV in November following the FDA’s approval of Ixchiq for the prevention of disease caused by chikungunya virus
Valneva’s chikungunya vaccine approved by FDA for adults at increased exposure risk
The decision makes Ixchiq, which is administered as a single injection, the world's first licensed vaccine against the mosquito-borne disease
Bavarian Nordic’s chikungunya vaccine candidate shows promise in late-stage trial
There is currently no approved vaccine or specific treatment for chikungunya virus infections